[go: up one dir, main page]

WO2005045054A3 - Procedes pour identifier des principes actifs ayant une influence sur la masse corporelle et l'accumulation de graisse - Google Patents

Procedes pour identifier des principes actifs ayant une influence sur la masse corporelle et l'accumulation de graisse Download PDF

Info

Publication number
WO2005045054A3
WO2005045054A3 PCT/EP2004/012555 EP2004012555W WO2005045054A3 WO 2005045054 A3 WO2005045054 A3 WO 2005045054A3 EP 2004012555 W EP2004012555 W EP 2004012555W WO 2005045054 A3 WO2005045054 A3 WO 2005045054A3
Authority
WO
WIPO (PCT)
Prior art keywords
obesity
methods
active substances
body mass
identifying active
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2004/012555
Other languages
German (de)
English (en)
Other versions
WO2005045054A2 (fr
Inventor
Gudrun Brockmann
Ulla Renne
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
FORSCHUNGSINSTITUT fur DIE BIOLOGIE LANDWIRTSCHAFTLICHER NUTZTIERE
Original Assignee
FORSCHUNGSINSTITUT fur DIE BIOLOGIE LANDWIRTSCHAFTLICHER NUTZTIERE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by FORSCHUNGSINSTITUT fur DIE BIOLOGIE LANDWIRTSCHAFTLICHER NUTZTIERE filed Critical FORSCHUNGSINSTITUT fur DIE BIOLOGIE LANDWIRTSCHAFTLICHER NUTZTIERE
Publication of WO2005045054A2 publication Critical patent/WO2005045054A2/fr
Publication of WO2005045054A3 publication Critical patent/WO2005045054A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des procédés pour identifier des principes actifs ayant une influence sur la masse corporelle et l'accumulation de graisse.
PCT/EP2004/012555 2003-11-07 2004-11-05 Procedes pour identifier des principes actifs ayant une influence sur la masse corporelle et l'accumulation de graisse Ceased WO2005045054A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10352510.6 2003-11-07
DE2003152510 DE10352510A1 (de) 2003-11-07 2003-11-07 Verfahren zur Identifizierung von Wirkstoffen zur Beeinflussung der Körpermasse und des Fettansatzes

Publications (2)

Publication Number Publication Date
WO2005045054A2 WO2005045054A2 (fr) 2005-05-19
WO2005045054A3 true WO2005045054A3 (fr) 2005-09-22

Family

ID=34559563

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2004/012555 Ceased WO2005045054A2 (fr) 2003-11-07 2004-11-05 Procedes pour identifier des principes actifs ayant une influence sur la masse corporelle et l'accumulation de graisse

Country Status (2)

Country Link
DE (1) DE10352510A1 (fr)
WO (1) WO2005045054A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1900826A1 (fr) * 2006-09-12 2008-03-19 Institut National de la Recherche Agronomique Marqueur génomique de la tendreté d'une viande

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001078726A1 (fr) * 2000-04-13 2001-10-25 Novartis Ag Nouvelles utilisations des imidazolylmethyl-pyridines
WO2003033513A1 (fr) * 2001-10-16 2003-04-24 Autogen Research Pty Ltd Genes exprimes de maniere differentielle, associes a l'obesite et au diabete de type 2

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6309853B1 (en) * 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001078726A1 (fr) * 2000-04-13 2001-10-25 Novartis Ag Nouvelles utilisations des imidazolylmethyl-pyridines
WO2003033513A1 (fr) * 2001-10-16 2003-04-24 Autogen Research Pty Ltd Genes exprimes de maniere differentielle, associes a l'obesite et au diabete de type 2

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BROCKMANN GUDRUN A ET AL: "Genome-wide search for loci controlling serum IGF binding protein levels of mice", FASEB JOURNAL, vol. 15, no. 6, April 2001 (2001-04-01), pages 978 - 987, XP002321321, ISSN: 0892-6638 *
BROCKMANN GUDRUN A ET AL: "Quantitative trait loci affecting body weight and fatness from a mouse line selected for extreme high growth", GENETICS, vol. 150, no. 1, September 1998 (1998-09-01), pages 369 - 381, XP002321319, ISSN: 0016-6731 *
BROCKMANN GUDRUN A ET AL: "Single QTL effects, epistasis, and pleiotropy account for two-thirds of the phenotypic F2 variance of growth and obesity in DU6i X DBA/2 mice", GENOME RESEARCH, vol. 10, no. 12, December 2000 (2000-12-01), pages 1941 - 1957, XP002321320, ISSN: 1088-9051 *
BROCKMANN GUDRUN A ET AL: "Using mouse models to dissect the genetics of obesity", TRENDS IN GENETICS, vol. 18, no. 7, July 2002 (2002-07-01), pages 367 - 376, XP004371951, ISSN: 0168-9525 *
KIM EUN-KYOUNG ET AL: "Expression of FAS within hypothalamic neurons: A model for decreased food intake after C75 treatment.", AMERICAN JOURNAL OF PHYSIOLOGY, vol. 283, no. 5 Part 1, November 2002 (2002-11-01), pages E867 - E879, XP002312241, ISSN: 0002-9513 *
LOFTUS T M ET AL: "REDUCED FOOD INTAKE AND BODY WEIGHT IN MICE TREATED WITH FATTY ACID SYNTHASE INHIBITORS", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, US, vol. 288, no. 5475, 30 June 2000 (2000-06-30), pages 2379 - 2381, XP008039591, ISSN: 0036-8075 *

Also Published As

Publication number Publication date
WO2005045054A2 (fr) 2005-05-19
DE10352510A1 (de) 2005-06-23

Similar Documents

Publication Publication Date Title
AP2280A (en) Compositions and methods for increasing telomeraseactivity.
PL1651042T3 (pl) Kompozycja chwastobójcza o zwiększonym działaniu chwastobójczym i sposób zwiększania działania chwastobójczego
WO2007133290A8 (fr) Anticorps anti-ox40l et méthodes correspondantes
WO2007044026A3 (fr) Compositions comportant du collagène modifié et leurs utilisations
WO2005110396A3 (fr) Lipides nitres et procedes de fabrication et d'utilisation associes
EP1664116A4 (fr) Anticorps ameliores possedant une fonction d'effecteur modifiee et procedes de fabrication associes
EP1660638A4 (fr) Lipoparticules comprenant des proteines, et procedes de production et d'utilisation de ces lipoparticules
IL174918A0 (en) Methods and reagents for the treatment of immunoinflammatory disorders
IL174185A0 (en) Methods and reagents for the treatment of immunoinflammatory disorders
IL187079A0 (en) An oligoadenylate synthetase 1 protein, therapeutic compositions containing the same and screening methods
WO2004031352A3 (fr) Variants d'interferons presentant des proprietes ameliorees
AU2003902868A0 (en) Muscle assessment
EP1711527A4 (fr) Anticorps specifiques de hla-dr, compositions et methodes associees
WO2007019373A3 (fr) Nouvelles formulations contenant du fenofibrate et de la statine et procedes de traitement associes
IL172510A0 (en) Antibodies and uses thereof
AUPS328902A0 (en) An incendiary
WO2004026892A3 (fr) Fragmentation d'adn
WO2005003157A3 (fr) Variantes de l'interferon a proprietes ameliorees
AU2003281094A1 (en) Identity verification
WO2004078142A3 (fr) Compositions et methodes de preventions et de traitement de maladies et d'etats pathologiques associes aux endotoxines
WO2005045054A3 (fr) Procedes pour identifier des principes actifs ayant une influence sur la masse corporelle et l'accumulation de graisse
EP1694845B8 (fr) Anticorps anticarcinomes et leurs utilisations
AU2003247216A1 (en) Novel sphinogmyelinase, the antibody against it, the antisense and the preparation method thereof
WO2006010077A3 (fr) Promedicaments de lonidamine et analogues de lonidamine
HK1092709A (en) Extract of nelumbinis semen for the treatment of depression

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase